Monday November 23 2009 | Biotechnology feed | All feeds
|
|
Monday November 23 2009 | Biotechnology feed | All feeds
|
|
|
RWJ-270201, a once daily treatment of influenza About 10% to 20% of U.S. residents will get the flu each year. As a result an average of about 20,000 people per year will die and 114,000 per year have to be admitted to the hospital. Anyone can get the flu and serious problems from flu can happen at any age although the elderly, people with chronic medical conditions, and very young children are more likely to get complications from flu. Inoculation is currently the best prevention of flu however antiviral agents are in development. Amantadine and rimantadine are used to treat and prevent influenza A infections, zanamivir and oseltamivir, both neuraminidase inhibitors are used against influenza A and B infections. Zanamivir is inhaled, oseltamivir is taken orally and both require twice daily doses. Current challenges are to identify novel molecules with improved pharmacodynamics that would allow once daily oral dosing thus reducing cost. RWJ-270201 is a unique neuraminidase inhibitor with high selectivity for the influenza neuraminidase and with an efficacy comparable to or better than earlier neuraminidase inhibitors against a wide range of influenza A and B isolates. This molecules is apparently active when given once daily and therefore represents a potential follow-up to existing anti-virals. Projects such as these are overviewed in full DiscoveryDossiers. DiscoveryDossiers ~ TherapeuticsAdvances ~ PharmaceuticalSolutions ~ LeadDiscovery ~ Purchase DiscoveryDossiersLeadDiscovery and BioPortfolio aims to provide reliable, insightful analysis on the biotechnology industry. However, this information is provided "as is" and no representations or warranties either express or implied of completeness, accuracy, or of any other nature are made with respect to this information. This information is neither an offer to sell nor a solicitation to buy the securities of any company. This information contains forward-looking statements, which involve risks and uncertainties which may not be listed. The biotechnology industry is an emerging industry and the securities of the companies mentioned in this report have a very high degree of risk and volatility. For this reason, this information is supplied on the condition that the reader will make his or her own determination as to its suitability for any purpose prior to any use of this information. The employees and officers of LeadDiscovery and BioPortfolio may hold positions in some or all of the stocks discussed in this report. This abstract has been produced by LeadDiscovery Ltd. Founded by life scientists for life scientists we aim to help industry identify cutting edge drug discovery options and academic/biotech institutions maximize the potential of their research. Abstracts strictly reflect the opinion of LeadDiscovery's editorial panel. While all reasonable efforts are made to ensure the accuracy of information provided LeadDiscovery and the publisher BioPortfolio, takes no responsibility for incorrect or misleading information. LeadDiscovery is designed for educational and drug development purposes only and is not intended or designed to offer medical advice or advice of any sort, and must not be used for such purpose. The information provided through LeadDiscovery and BioPortfolio should not be used for diagnosing or treating a health problem or a disease and no reliance should be placed on any information contained in this abstract or elsewhere on LeadDiscovery's and BioPortfolio's website. It is not intended to be a substitute for professional care. If you have or suspect you may have a health problem, you should consult your physician or other health care provider. |
|
|
